ІМБРУВІКА

Product Overview

About ІМБРУВІКА

ІМБРУВІКА is a prescription medicine containing the active ingredient Ibrutinib. It is used in the treatment of certain blood cancers, specifically mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). ІМБРУВІКА belongs to a class of medicines known as Bruton's tyrosine kinase (BTK) inhibitors, which help control the growth and spread of cancer cells by interfering with key signaling pathways involved in their survival and proliferation.

Key Benefits & Uses

• Targets and inhibits Bruton's tyrosine kinase (BTK), a protein essential for the survival and growth of malignant B-cells
• Used for the treatment of mantle cell lymphoma (MCL) in patients who have received prior therapy
• Indicated for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Active Ingredient & Action

The active ingredient in ІМБРУВІКА, Ibrutinib, works by irreversibly binding to Bruton's tyrosine kinase (BTK), an enzyme crucial for B-cell receptor signaling. By blocking this pathway, Ibrutinib prevents the survival and proliferation of malignant B-cells, leading to their apoptosis. This targeted mechanism offers a more precise approach to treating B-cell malignancies compared to traditional chemotherapy.

Important Notes

ІМБРУВІКА should be taken exactly as prescribed by your healthcare provider. It may cause side effects such as bleeding, infections, hypertension, and diarrhea. Regular monitoring of blood counts and liver function is recommended during treatment. Patients should avoid live vaccines and inform their doctor of any signs of unusual bleeding or infection. ІМБРУВІКА is not recommended for use in children. Always consult your physician before starting or discontinuing this medication.